HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

tolafentrine

a mixed-type phosphodiesterase (PDE) III/IV inhibitor

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - tolafentrine: 3

Experts

1.	Ghofrani, Hossein Ardeschir: 3 articles (03/2011 - 04/2004)
2.	Grimminger, Friedrich: 3 articles (03/2011 - 04/2004)
3.	Schermuly, Ralph Theo: 3 articles (03/2011 - 04/2004)
4.	Schudt, Christian: 3 articles (03/2011 - 04/2004)
5.	Seeger, Werner: 3 articles (03/2011 - 04/2004)
6.	Weissmann, Norbert: 3 articles (03/2011 - 04/2004)
7.	Pullamsetti, Soni: 2 articles (11/2005 - 04/2004)
8.	Fleming, Ingrid: 1 article (03/2011)
9.	Leiper, James: 1 article (03/2011)
10.	Mayer, Konstantin: 1 article (03/2011)

Related Diseases

1.	Pulmonary Arterial Hypertension 03/22/2011 - "In monocrotaline-induced pulmonary arterial hypertension in rats, the effects of inhaled tolafentrine on DDAH expression and activity were investigated. " 11/01/2005 - "The aim of the study was to assess the chronic effects of combined phosphodiesterase 3/4 inhibitor tolafentrine, administered by inhalation, during monocrotaline-induced pulmonary arterial hypertension (PAH) in rats. "
2.	Vascular Remodeling 11/01/2005 - "Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration." 04/30/2004 - "Moreover, when iloprost plus tolafentrine was used for late therapeutic intervention, with infusion from days 28 to 42 after full establishment of severe pulmonary hypertension and cor pulmonale, hemodynamic, gas exchange, and cardiac and pulmonary vascular remodeling changes were significantly reversed. "
3.	Pulmonary Hypertension 04/30/2004 - "Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension." 04/30/2004 - "Moreover, when iloprost plus tolafentrine was used for late therapeutic intervention, with infusion from days 28 to 42 after full establishment of severe pulmonary hypertension and cor pulmonale, hemodynamic, gas exchange, and cardiac and pulmonary vascular remodeling changes were significantly reversed. " 11/01/2005 - "When chronically nebulized from day 28 to 42 (12 daily aerosol maneuvers), after full establishment of severe pulmonary hypertension, tolafentrine reversed about 60% of all hemodynamic abnormalities, right heart hypertrophy and monocrotaline-induced structural lung vascular changes, including the proportion of pulmonary artery muscularization. " 04/30/2004 - "We investigated acute and chronic effects of iloprost, a long-acting prostacyclin analogue, and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in monocrotaline-induced pulmonary hypertension in rats. "
4.	Pulmonary Heart Disease (Cor Pulmonale) 04/30/2004 - "Moreover, when iloprost plus tolafentrine was used for late therapeutic intervention, with infusion from days 28 to 42 after full establishment of severe pulmonary hypertension and cor pulmonale, hemodynamic, gas exchange, and cardiac and pulmonary vascular remodeling changes were significantly reversed. "
5.	Cardiomegaly (Heart Hypertrophy) 11/01/2005 - "When chronically nebulized from day 28 to 42 (12 daily aerosol maneuvers), after full establishment of severe pulmonary hypertension, tolafentrine reversed about 60% of all hemodynamic abnormalities, right heart hypertrophy and monocrotaline-induced structural lung vascular changes, including the proportion of pulmonary artery muscularization. "

Related Drugs and Biologics

1.	Monocrotaline
2.	Phosphoric Diester Hydrolases (Phosphodiesterases)
3.	Iloprost (Ventavis)
4.	Epoprostenol (Prostacyclin)
5.	Aerosols